The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Current understanding of Alzheimer’s disease diagnosis and treatment
Open accessAbstract
Alzheimer’s disease is the most common cause of dementia worldwide, with the prevalence continuing to grow in part because of the aging world population. This neurodegenerative disease process is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria as well as fluid and imaging biomarkers. Treatment is currently targeted toward symptomatic therapy, although trials are underway that aim to reduce the production and overall burden of pathology within the brain. Here, we discuss recent advances in our understanding of the clinical evaluation and treatment of Alzheimer’s disease, with updates regarding clinical trials still in progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, both PET imaging and CSF analysis exhibit similar accuracy, and suggest that the optimum test for the diagnosis will depend upon patient/provider preference, cost and availability of facilities [37].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [37]
In the citing paper
“Current therapeutics to ameliorate and control the cognitive and behavioral symptoms by targeting the NMDA receptor prevent Ca2+ induced excitotoxicity [2, 9–11], and memantine was approved for this purpose in 2003.”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzen, E. (2008) · Wiley eBooks · doi:10.1002/9780470373699.speced0655 · Cited by 8,467
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Mechanisms of Gamma Oscillations
Buzsáki, G., & Wang, X.-J. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150444 · Cited by 2,796
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Cited by
Sorted by citations
Items 201–300 of 1,000
Neurodegenerative diseases and neuroinflammation-induced apoptosis
Huang, S., Lu, Y., Fang, W., Huang, Y., Li, Q., & Xu, Z. (2025) · Open Life Sciences · doi:10.1515/biol-2022-1051 · Cited by 32
Jeon, S. H., Kim, N., Ju, Y., Gee, M. S., Lee, D., & Lee, J. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228425 · Cited by 32
Identification of potential biomarkers for pathogenesis of Alzheimer’s disease
Wang, H., Han, X., & Gao, S. (2021) · Hereditas · doi:10.1186/s41065-021-00187-9 · Cited by 34
The Role of Heme and Copper in Alzheimer’s Disease and Type 2 Diabetes Mellitus
Pal, I., & Dey, S. G. (2023) · JACS Au · doi:10.1021/jacsau.2c00572 · Cited by 32
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Class balancing diversity multimodal ensemble for Alzheimer’s disease diagnosis and early detection
Francesconi, A., di Biase, L., Cappetta, D., Rebecchi, F., Soda, P., Sicilia, R., & Guarrasi, V. (2025) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2025.102529 · Cited by 30
“For the diagnostic tasks, we use m = 4 data modalities (Section 4.1), excluding neuropsychological test scores to avoid bias, as AD diagnosis often relies on such tests [32].”
InfluentialDas, S. S., Gopal, P. M., Thomas, J. V., Mohan, M. C., Thomas, S. C., Maliakel, B. P., Krishnakumar, I. M., & Chakrapani, P. S. B. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1222708 · Cited by 35
Sundararajan, V., Venkatasubbu, G. D., & Mohideen, S. S. (2021) · 3 Biotech · doi:10.1007/s13205-021-02706-x · Cited by 30
Wei, W., Wang, Y., Zhang, J., Gu, Q., Liu, X., Song, L., Chai, Z., Guo, M., Yu, J., & Ma, C. (2021) · Folia Neuropathologica · doi:10.5114/fn.2021.105130 · Cited by 30
Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview
Štrac, D. Š., Konjevod, M., Šagud, M., Perković, M. N., Erjavec, G. N., Vuić, B., Šimić, G., Vukić, V., Mimica, N., & Pivac, N. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s284615 · Cited by 30
Kim, T., Son, T., Klatt, D., & Yao, X. (2021) · Neurophotonics · doi:10.1117/1.nph.8.3.035002 · Cited by 30
Melatonin and Sleep Disturbances in Alzheimer’s Disease
Prodhan, A. H. M. S. U., Cavestro, C., Kamal, M. A., & Islam, M. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210804155617 · Cited by 30
Miao, S., He, Q., Li, C., Wu, Y., Liu, M., Chen, Y., Qi, S., & Gong, K. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2102657 · Cited by 29
Yang, X., Zhou, P., Zhao, Z., Li, J., Fan, Z., Li, X., Cui, Z., & Fu, A. (2023) · Antioxidants · doi:10.3390/antiox12112006 · Cited by 29
Sivamaruthi, B. S., Kapoor, D. U., Kukkar, R. R., Gaur, M., Elossaily, G. M., Prajapati, B. G., & Chaiyasut, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122666 · Cited by 29
Senescence Targeting Methods Impact Alzheimer’s Disease Features in 3xTg Mice
Ng, P. Y., Zhang, C., Li, H., & Baker, D. J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230465 · Cited by 32
de Farias, J. M., Tramontin, N. D. S., Pereira, E. V., de Moraes, G. L., Furtado, B. A. G., Tietbohl, L. T. W., Pereira, B. D. C., Simon, K. U., & Muller, A. P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02411-z · Cited by 29
Mechanism of Tripeptide Trimming of Amyloid β-Peptide 49 by γ-Secretase
Bhattarai, A., Devkota, S., Do, H. N., Wang, J., Bhattarai, S., Wolfe, M. S., & Miao, Y. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c10533 · Cited by 30
TUFM is involved in Alzheimer’s disease-like pathologies that are associated with ROS
Zhong, B., Zhou, G., Song, L., Wen, Q., Deng, X., Ma, Y., Hu, L., & Chen, G. (2021) · The FASEB Journal · doi:10.1096/fj.202002461r · Cited by 28
Stergiou, N., Wuensche, T. E., Schreurs, M., Mes, I., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Helboe, L., Vergo, S. B., Christensen, S., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06109-3 · Cited by 27
Chaitanuwong, P., Singhanetr, P., Chainakul, M., Arjkongharn, N., Ruamviboonsuk, P., & Grzybowski, A. E. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00526-0 · Cited by 28
Salcedo, C., Garcia, V. P., García‐Adán, B., Ameen, A. O., Gegelashvili, G., Waagepetersen, H. S., Freude, K., & Aldana, B. I. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16014 · Cited by 30
Agrawal, M., Singhal, M., Semwal, B. C., Arora, S., Singh, B., Sikarwar, V., Sethi, P., Chaudhary, H., Akram, W., Bhargva, S., et al. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100492 · Cited by 28
Glycosylation in aging and neurodegenerative diseases
Zhang, W., Chen, T., Zhao, H., & Ren, S. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024136 · Cited by 27
Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
Valeri, A., & Mazzon, E. (2021) · Molecules · doi:10.3390/molecules26206313 · Cited by 26
Second Sphere Interactions in Amyloidogenic Diseases
Roy, M., Nath, A. K., Pal, I., & Dey, S. G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00941 · Cited by 29
Elhabak, M., Salama, A. A. A., & Salama, A. H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122588 · Cited by 27
Wu, C., Zhao, Y., Geng, Y., Shi, K., & Zhou, S. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.172086 · Cited by 27
Multitarget-Directed Ligands for Alzheimer’s Disease: Recent Novel MTDLs and Mechanistic Insights
Almaghrabi, M. (2025) · Pharmaceuticals · doi:10.3390/ph18111685 · Cited by 33
Cazarin, C. A., Dalmagro, A. P., Gonçalves, A. E., Boeing, T., da Silva, L. M., Corrêa, R., Klein‐Júnior, L. C., Pinto, B. C., Lorenzett, T. S., Sobrinho, T. U. D. C., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112945 · Cited by 28
Effects of Curcumin and Boric Acid Against Neurodegenerative Damage Induced by Amyloid Beta (1-42)
Hacıoğlu, C., Kar, F., Kar, E., Kara, Y., & Kanbak, G. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02511-2 · Cited by 27
Discovery of Novel Markers for Identifying Cognitive Decline Using Neuron-Derived Exosomes
Zhong, J., Ren, X., Liu, W., Wang, S., Lv, Y., Nie, L., Lin, R., Tian, X., Yang, X., Zhu, F., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.696944 · Cited by 28
Lin, X., Chen, L., Baglietto‐Vargas, D., Kamalipour, P., Ye, Q., LaFerla, F. M., Nitz, D. A., Holmes, T. C., & Xu, X. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105562 · Cited by 27
Ye, H., Zhu, Q., Yao, Y., Jin, Y., & Zhang, D. (2022) · The Visual Computer · doi:10.1007/s00371-021-02354-5 · Cited by 27
Li, W., Sun, L., Yue, L., & Xiao, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1120495 · Cited by 30
Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers
Ansari, M. A., Tripathi, T., Venkidasamy, B., Monziani, A., Rajakumar, G., Alomary, M. N., Alyahya, S. A., Onimus, O., D’souza, N., Barkat, M. A., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03730-z · Cited by 29
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26
Battineni, G., Chintalapudi, N., & Amenta, F. (2024) · JMIR Aging · doi:10.2196/59370 · Cited by 27
Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care
Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 28
Alzheimer’s Disease Research Using Human Microglia
Lue, L., Beach, T. G., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8080838 · Cited by 29
The Mitochondrial Hsp90 TRAP1 and Alzheimer’s Disease
Dekker, F. A., & Rüdiger, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.697913 · Cited by 28
Gök, H. N., Luca, S. V., Ay, S. T., Komsta, Ł., Salmas, R. E., Orhan, İ. E., & Skalicka‐Woźniak, K. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.130775 · Cited by 27
Zeng, J., Liu, J., Qu, Q., Zhao, X., & Zhang, J. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02749-2 · Cited by 28
rTMS alleviates AD-induced cognitive impairment by inhibitng apoptosis in SAMP8 mouse
Bao, Z., Bao, L., Han, N., Hou, Y., & Feng, F. (2021) · Aging · doi:10.18632/aging.203796 · Cited by 26
Is oral lipid-based delivery for drug targeting to the brain feasible?
Brookes, A., Ji, L., Bradshaw, T. D., Stocks, M. J., Gray, D. A., Butler, J., & Gershkovich, P. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.004 · Cited by 28
Li, Y., Wang, H., Chen, L., Wei, K., Liu, Y., Han, Y., & Xia, X. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01051-z · Cited by 26
A Systematic Review of the Effects of Capsaicin on Alzheimer’s Disease
Inyang, D., Saumtally, T., Nnadi, C. N., Devi, S., & So, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210176 · Cited by 28
Marei, H. E. S., Khan, M. U. A., & Hasan, A. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00504-2 · Cited by 27
Fulcher, J. M., Ives, A. N., Tasaki, S., Kelly, S. S., Williams, S., Fillmore, T., Zhou, M., Moore, R., Qian, W., Paša‐Tolić, L., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100983 · Cited by 25
Beaurain, M., Salabert, A., Ribeiro, M. J., Arlicot, N., Damier, P., Jeune, F. L., Démonet, J., & Payoux, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00268 · Cited by 26
Gu, Y., & Zhu, D. (2021) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200108 · Cited by 24
Li, X., Cheng, Y.-X., Qin, Y.-P., Gao, H., Wang, G., Song, H., Wang, Y., & Cai, B. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab148 · Cited by 25
Verheijen, M. C. T., Krauskopf, J., Caiment, F., Nazaruk, M., Wen, Q. F., van Herwijnen, M. H. M., Hauser, D. A., Gajjar, M. K., Verfaillie, C. M., Vermeiren, Y., et al. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.12.009 · Cited by 25
Çağlar, Ö., Arslan, M. E., Öner, S., Cacciatore, I., Stefano, A. D., Mardinoğlu, A., & Türkez, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158249 · Cited by 25
Mattke, S., Filho, O. C. D. S., Hanson, M., Mateus, E. F., Neto, J. P. R., de Souza, L. C., Schultz, R. R., & Pinto, R. P. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12778 · Cited by 27
New Drug Design Avenues Targeting Alzheimer’s Disease by Pharmacoinformatics-Aided Tools
Arrué, L., Cigna-Méndez, A., Barbosa, T., Borrego-Muñoz, P., Struve-Villalobos, S., Oviedo, V., Martínez-García, C., Sepúlveda-Lara, A., Millán, N., Montesinos, J. C. E. M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091914 · Cited by 28
Advances in the roles and mechanisms of lignans against Alzheimer’s disease
Han, N., Wen, Y., Liu, Z., Zhai, J., Li, S., & Yin, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.960112 · Cited by 25
Wang, C., Xu, T., Yu, W., Li, T., Han, H., Zhang, M., & Ming, T. (2022) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2022.10.010 · Cited by 25
Palaniyandi, T., Kanagavalli, B., Prabhakaran, P., Viswanathan, S., Wahab, M. R. A., Natarajan, S., Moorthy, S. K. K., & Saravanan, K. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.151997 · Cited by 25
Telomerase reverse transcriptase and neurodegenerative diseases
Yu, X., Liu, M., Zheng, C., Liu, Y., Wang, Z., & Wang, Z.-Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165632 · Cited by 25
Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes
Pajk, S., Knez, D., Košak, U., Zorović, M., Brazzolotto, X., Coquelle, N., Nachon, F., Colletier, J., Živin, M., Stojan, J., et al. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1710502 · Cited by 25
Guzzon, A., Rebba, V. S., Paccagnella, O., Rigon, M., & Boniolo, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285305 · Cited by 28
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 24
β-lactam antibiotics to tame down molecular pathways of Alzheimer's disease
Kumari, S., & Deshmukh, R. R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173877 · Cited by 24
Yin, P., Xue, Y., Wang, T., Zhong, D., & Li, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.609679 · Cited by 24
Babaee, S., Chehardoli, G., Akbarzadeh, T., Zolfigol, M. A., Mahdavi, M. R., Rastegari, A., Moghadam, F. H., & Najafi, Z. (2021) · Chemistry & Biodiversity · doi:10.1002/cbdv.202000924 · Cited by 24
ATP-binding cassette transporters and neurodegenerative diseases
Katzeff, J. S., & Kim, W. S. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210012 · Cited by 23
Lee, J.-E., Kwon, S., Jin, C., Cho, S., Park, S.-U., Jung, W., Moon, S., Park, J., Ko, C., & Cho, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020174 · Cited by 24
Research progress of the CXCR4 mechanism in Alzheimer's disease
Wang, Q., Fang, C., Huang, X., & Xue, L. (2022) · Ibrain · doi:10.1002/ibra.12026 · Cited by 24
Vicente-Zurdo, D., Gómez-Gómez, B., Romero, I., Rosales‐Conrado, N., León‐González, M. E., & Madrid, Y. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.340949 · Cited by 24
NADPH Oxidases in Neurodegenerative Disorders: Mechanisms and Therapeutic Opportunities
Fiadeiro, M. B., Diogo, J. C., Silva, A., Kim, Y., & Cristóvão, A. C. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0002 · Cited by 25
Systematic review and meta‐analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue
Heberle, B. A., Fox, K. L., Libermann, L. L., Xavier, S. R. M., Dallarosa, G. T., Santos, R. C., Fardo, D. W., Viola, T. W., & Ebbert, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70025 · Cited by 30
Adenosine Receptors in Neuroinflammation and Neurodegeneration
Salmaso, V., Menin, S., Moro, S., Spalluto, G., & Federico, S. (2025) · Cells · doi:10.3390/cells14201585 · Cited by 25
Weng, G., Zhou, B., Liu, T., Huang, Z., & Huang, S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s290030 · Cited by 23
Ashraf, H., Solla, P., & Sechi, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15091077 · Cited by 23
Tau-Mediated Dysregulation of Neuroplasticity and Glial Plasticity
Koller, E. J., & Chakrabarty, P. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00151 · Cited by 23
Does Diet Have a Role in the Treatment of Alzheimer's Disease?
Thelen, M., & Brown‐Borg, H. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.617071 · Cited by 24
Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease
Nichols, J. B., Malek-Ahmadi, M., Tariot, P. N., Serrano, G. E., Sue, L. I., & Beach, T. G. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa160 · Cited by 22
Detecting Alzheimer’s Disease Using Interactional and Acoustic Features from Spontaneous Speech
Nasreen, S., Hough, J., & Purver, M. (2021) · Interspeech 2021 · doi:10.21437/interspeech.2021-1526 · Cited by 22
A feature-aware multimodal framework with auto-fusion for Alzheimer’s disease diagnosis
Zhang, M., Cui, Q., Lü, Y., & Li, W. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108740 · Cited by 23
Jia, S., Guan, H., Zhang, S., & Li, Q. (2024) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v52i5.1680 · Cited by 22
Wang, H., Pan, J., Zhang, M., & Tan, Z. F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599048 · Cited by 28
Chronic stress and Alzheimer's disease
Mohammadi, S., Zandi, M., Kataj, P. D., & Karimi‐Zandi, L. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2216 · Cited by 22
Advances in nonlinear optical microscopy techniques for in vivo and in vitro neuroimaging
Pallen, S., Shetty, Y., Das, S. K., Vaz, J. M., & Mazumder, N. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00832-7 · Cited by 21
The Cardiac Dysfunction Caused by Metabolic Alterations in Alzheimer's Disease
Murphy, J., Le, T. N. V., Fedorova, J., Yang, Y., Krause‐Hauch, M., Davitt, K., Zoungrana, L. I., Fatmi, M. K., Lesnefsky, E. J., Li, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.850538 · Cited by 23
Li, W., Gao, J.-Y., Lin, S.-Y., Pan, S.-T., Xiao, B., Ma, Y.-T., Xie, K., Shen, W., Liu, Z.-T., Li, G.-Y., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02784-9 · Cited by 23
Wei, Y.-D., Chen, X.-X., Yang, L., Gao, X., Xia, Q., Qi, C., & Ge, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105385 · Cited by 23
Ryan, D. K., Karhunen, V., Su, B., Traylor, M., Richardson, T. G., Burgess, S., Tzoulaki, I., & Gill, D. (2022) · Neurology Genetics · doi:10.1212/nxg.0000000000200014 · Cited by 21
Xie, M., Gu, S., Hong, Y., Liu, Y., Rong, X., Lu, W., Liu, H., Algradi, A. M., Naseem, A., Shu, Z., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116392 · Cited by 22
Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
Eddin, A. N., Hamsho, K., Adi, G., Al-Rimawi, M., Alfuwais, M., Rab, S. A., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1210191 · Cited by 26
Joshi, A., Wang, D., Watterson, S., McClean, P. L., Behera, C. K., Sharp, T., & Wong‐Lin, K. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108118 · Cited by 22
Inflammatory Association between Periodontal Disease and Systemic Health
Hasan, F., Tandon, A., AlQallaf, H., John, V., Sinha, M., & Gibson, M. P. (2025) · Inflammation · doi:10.1007/s10753-025-02317-1 · Cited by 37
Gene and RNA Editing: Revolutionary Approaches to Treating Diseases
Li, J., Huang, J., Liao, Y., Hu, T., Wang, C., Zhang, W., & Huang, C. (2025) · MedComm · doi:10.1002/mco2.70389 · Cited by 23
Shen, S., Wang, X., Lv, H., Shi, Y., & Xiao, L. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbab054 · Cited by 21
Promising protein biomarkers in the early diagnosis of Alzheimer’s disease
Sharma, L. K., Sharma, A., Kumar, D., Asthana, M. K., Lalhlenmawia, H., Kumar, A., Bhattacharyya, S., & Kumar, D. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00847-9 · Cited by 22
Nakamya, M. F., Sil, S., Buch, S. J., & Hakami, R. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.840364 · Cited by 22
Anoush, M., Pourmansouri, Z., Javadi, R., GhorbanPour, B., Sharafi, A., Mohamadpour, H., Anarkooli, I. J., & Andalib, S. (2022) · ACS Omega · doi:10.1021/acsomega.2c00231 · Cited by 21
Chen, S., Hu, N., Wang, H., & Li, G. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105104 · Cited by 21
LncRNA HOTAIR in exercise-induced neuro-protective function in Alzheimer’s disease
Lü, J., Liu, L., Chen, J., Zhi, J., Li, J., Li, L., & Jiang, Z. (2022) · Folia Neuropathologica · doi:10.5114/fn.2022.118961 · Cited by 22
Formulation strategies for nose-to-brain drug delivery in Alzheimer's disease
Vohra, M., Amir, M., Sharma, A., & Wadhwa, S. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100075 · Cited by 21
Metadata
- Authors
- Weller, J., & Budson, A.
- Affiliations
- Boston University (US)
- Corresponding author
- Weller, Jason
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2018-07-31
- Volume
- 7
- Pages
- 1161
- ISSN
- 2046-1402 (ISSN-L)
- PMC
- PMC6073093
- OpenAlex
- W2885706121
- Cited by
- 1,083
- References
- 53
- Citations by year
- 2026: 67 · 2025: 155 · 2024: 147 · 2023: 176 · 2022: 221 · 2021: 194 · 2020: 92 · 2019: 29 · 2018: 2
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- F1000Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute on Aging (P30AG013846)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, dementia, amyloid plaques, tau hyperphosphorylation, neurofibrillary tangles, biomarkers, diagnosis, symptomatic treatment, disease-modifying therapy, clinical trials, neurodegeneration
- MeSH terms
- Alzheimer Disease, Humans, Nerve Net, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
